|
Summary |
|||
|
|
|||
|
|
· |
Group sales +6% CER on a reported basis and +1% CER pro-forma |
|
|
|
|
- |
Pharmaceuticals £14.2 billion, -7% (-1% pro-forma); Vaccines £3.7 billion, +19% (+3% pro-forma); Consumer Healthcare £6 billion, +44% (+6% pro-forma) |
|
|
|
|
|
|
|
· |
£2 billion of new product sales driven by HIV (Tivicay, Triumeq), Respiratory (Relvar/Breo, Anoro,Incruse) and Meningitis vaccines (Menveo, Bexsero) |
|
|
|
|
- |
Growing sales contribution: Q4 sales £682 million, (Q3: £591 million) |
|
|
|
- |
Nucala, a new biologic treatment for severe asthma, launched at the end of 2015 |
|
|
|
- |
New product sales now expected to reach £6 billion target up to two years earlier (2018 vs 2020) |
|
|
|
|
|
|
|
· |
Integration and restructuring programme on schedule |
|
|
|
|
- |
£1 billion incremental annual cost savings delivered in 2015 for costs of £1.9 billion |
|
|
|
- |
On track to deliver £3 billion of annual cost savings by end 2017 |
|
|
|
|
|
|
|
· |
2015 core EPS 75.7p, -15% CER, ahead of financial guidance |
|
|
|
|
- |
Reflects short-term dilution from transaction partly offset by integration and restructuring benefits |
|
|
|
|
|
|
|
· |
2015 total EPS 174.3p, +>100% CER |
|
|
|
|
- |
Reflects impact of transaction gains, partly offset by restructuring charges and revaluation of the contingent consideration relating to improved outlook for HIV business |
|
|
|
|
|
|
|
· |
2016 core EPS percentage growth expected to reach double digits CER |
|
|
|
|
- |
If FX rates held at January average levels estimated impact of +5% on 2016 Sterling core EPS growth |
|
|
|
|
|
|
|
· |
2015 ordinary dividend of 80p and special dividend of 20p confirmed |
|
|
|
|
- |
Special dividend to be paid alongside Q4 ordinary dividend in April 2016 |
|
|
|
- |
Continue to expect 80p full year dividend for 2016 and 2017 |
|
|
|
|
|
|
|
· |
New R&D portfolio of ~40 assets to drive long-term performance; multiple development milestones expected in 2016/2017 |
|
|
|
|
- |
Up to 10 regulatory filings include Shingrix (shingles vaccine), sirukumab (RA), Benlysta SC (lupus) and ICS/LABA/LAMA (COPD) |
|
|
|
- |
Up to 10 Phase lll starts include cabotegravir (HIV), daprodustat (anaemia) and Men ABCWY vaccine |
|
|
|
- |
Up to 20 Phase ll starts in Immuno-inflammation, Oncology, Respiratory and Infectious diseases |
|
|
|
- |
Estimated R&D rate of return maintained at 13% |
